# US 2015/0105341 A1 · Substituted nucleosides, nucleotides and analogs thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0105341 A1
- Document ID: US20150105341A1
- Status: Published application
- Kind: A1
- Application number: 14/510,451
- Filed: 2014-10-09
- Published: 2015-04-16
- Earliest claimed: 2013-10-11
- Assignees: Alios BioPharma, Inc.
- Applicants: Alios BioPharma, Inc.
- Inventors: Leonid Beigelman; Guangyi Wang; David Bernard Smith; Marija Prhavc; Christian Andreas Jekle; Jerome Deval
- Web page: https://patentgrep.com/patent/US20150105341A1

## CPC

- C07H 19/20: with the saccharide radical esterified by phosphoric or polyphosphoric acids
- A61K 31/7052: having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K 31/7064: containing condensed or non-condensed pyrimidines
- A61K 31/7072: having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
- A61K 31/7076: containing purines, e.g. adenosine, adenylic acid
- A61K 31/708: having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
- A61P 31/14: for RNA viruses
- A61P 31/16: for influenza or rhinoviruses
- C07H 19/06: Pyrimidine radicals
- C07H 19/10: with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H 19/11: containing cyclic phosphate
- C07H 19/16: Purine radicals
- C07H 19/207: the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide
- C07H 19/213: containing cyclic phosphate
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Disclosed herein are nucleosides, nucleotides and nucleotide analogs, methods of synthesizing the same and methods of treating diseases and/or conditions such as a Picornavirus and/or Flaviviridae infection with one or more nucleosides, nucleotides and nucleotide analogs.

## Claims

### Claim 1

A method for ameliorating or treating a viral infection comprising contacting a cell infected with the virus with an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein the compound of Formula (I) has the structure:
wherein:
B1A is an optionally substituted heterocyclic base or an optionally substituted heterocyclic base with a protected amino group;
- - - - - - - - is absent or a single bond, provided that both - - - - - - - - are absent or both - - - - - - - - are a single bond;
when - - - - - - - - are both absent, then Z1 is absent, O1 is OR1A, R3A is selected from the group consisting of H, halo, OH, —OC(═O)R″A and an optionally substituted O-linked amino acid, R4A is selected from the group consisting of H, OH, halo, N3, —OC(═O)R″B, an optionally substituted O-linked amino acid and NR″B1R″B2, or R3A and R4A are both an oxygen atom connected via a carbonyl to form a 5-membered ring;
when - - - - - - - - are each a single bond, then Z1 is
O1 is O, R3A is O; R4A is selected from the group consisting of H, OH, halo, N3, —OC(═O)R″B, an optionally substituted O-linked amino acid and NR″B1R″B2; and R1B is selected from the group consisting of O−, OH, an —O-optionally substituted C1-6 alkyl.
an optionally substituted N-linked amino acid and an optionally substituted N-linked amino acid ester derivative;
Ra1 and Ra2 are independently hydrogen or deuterium;
RA is hydrogen, deuterium, an unsubstituted C1-3 alkyl, an unsubstituted C2-4 alkenyl, an unsubstituted C2-3 alkynyl or cyano;
R1A is selected from the group consisting of hydrogen, an optionally substituted acyl, an optionally substituted O-linked amino acid,
R2A is hydrogen, halo, an unsubstituted C1-4 alkyl, an unsubstituted C2-4 alkenyl, an unsubstituted C2-4 alkynyl, —CHF2, —(CH2)1-6 halogen, —(CH2)1-6N3, —(CH2)1-6NH2 or —CN;
R5A is selected from the group consisting of H, halo, OH, an optionally substituted C1-6 alkyl, an optionally substituted C2-6 alkenyl and an optionally substituted C2-6 alkynyl;
R6A, R7A and R8A are independently selected from the group consisting of absent, hydrogen, an optionally substituted C1-24 alkyl, an optionally substituted C2-24 alkenyl, an optionally substituted C2-24 alkynyl, an optionally substituted C3-6 cycloalkyl, an optionally substituted C3-6 cycloalkenyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted aryl(C1-6 alkyl), an optionally substituted *-(CR15AR16A)p—O—C1-24 alkyl, an optionally substituted *-(CR17AR18A)q—O—C1-24 alkenyl,
or
R6A is
and R7A is absent or hydrogen; or
R6A and R7A are taken together to form a moiety selected from the group consisting of an optionally substituted
and an optionally substituted
wherein the oxygens connected to R6A and R7A, the phosphorus and the moiety form a six-membered to ten-membered ring system;
R9A is independently selected from the group consisting of an optionally substituted C1-24 alkyl, an optionally substituted C2-24 alkenyl, an optionally substituted C2-24 alkynyl, an optionally substituted C3-6 cycloalkyl, an optionally substituted C3-6 cycloalkenyl NR30AR31A an optionally substituted N-linked amino acid and an optionally substituted N-linked amino acid ester derivative;
R10A and R11A are independently an optionally substituted N-linked amino acid or an optionally substituted N-linked amino acid ester derivative;
R12A and R13A are independently absent or hydrogen;
R14A is O−, OH or methyl;
each R15A, each R16A, each R17A and each R18A are independently hydrogen, an optionally substituted C1-24 alkyl or an alkoxy;
R19A, R20A, R22A, R23A, R2B, R3B, R5B and R6B are independently selected from the group consisting of hydrogen, an optionally substituted C1-24 alkyl and an optionally substituted aryl;
R21A and R4B are independently selected from the group consisting of hydrogen, an optionally substituted C1-24 alkyl, an optionally substituted aryl, an optionally substituted —O—C1-24 alkyl, an optionally substituted —O-aryl, an optionally substituted —O-heteroaryl and an optionally substituted —O-monocyclic heterocyclyl;
R24A and R7B are independently selected from the group consisting of hydrogen, an optionally substituted C1-24 alkyl, an optionally substituted aryl, an optionally substituted —O—C1-24 alkyl, an optionally substituted —O-aryl, an optionally substituted —O-heteroaryl, an optionally substituted —O-monocyclic heterocyclyl and
R25A, R26A, R29A, R8B and R9B are independently selected from the group consisting of hydrogen, an optionally substituted C1-24 alkyl and an optionally substituted aryl;
R27A1 and R27A2 are independently selected from the group consisting of —C≡N, an optionally substituted C2-8 organylcarbonyl, an optionally substituted C2-8 alkoxycarbonyl and an optionally substituted C2-8 organylaminocarbonyl;
R28A is selected from the group consisting of hydrogen, an optionally substituted C1-24 alkyl, an optionally substituted C2-24 alkenyl, an optionally substituted C2-24 alkynyl, an optionally substituted C3-6 cycloalkyl and an optionally substituted C3-6 cycloalkenyl;
R30A and R31A are independently selected from the group consisting of hydrogen, an optionally substituted C1-24 alkyl, an optionally substituted C2-24 alkenyl, an optionally substituted C2-24 alkynyl, an optionally substituted C3-6 cycloalkyl, an optionally substituted C3-6 cycloalkenyl and an optionally substituted aryl(C1-4 alkyl);
R″A and each R″B are independently an optionally substituted C1-24 alkyl;
each R″B1 and each R″B2 are independently hydrogen and an optionally substituted C1-6 alkyl;
m is 0 or 1;
p and q are independently 1, 2 or 3;
r and s are independently 0, 1, 2 or 3;
t is 1 or 2;
u and y can be independently 3, 4 or 5;
v and w are 1, and
Z1A, Z2A, Z3A, Z4A, Z1B and Z2B are independently O or S;
wherein the virus selected from the group consisting of a Picornaviridae virus and a Flaviviridae virus; and
provided that when the Flaviviridae virus is hepatitis C virus, then the compound of Formula (I), or a pharmaceutically acceptable salt thereof, cannot be selected from the group consisting of:
or a pharmaceutically acceptable salt of the foregoing.

### Claim 2 (depends on 1)

The method of claim 1, wherein the virus is a member of the Picornaviridae virus family.

### Claim 3

(canceled)

### Claim 4

(canceled)

### Claim 5

(canceled)

### Claim 6

(canceled)

### Claim 7

(canceled)

### Claim 8

(canceled)

### Claim 9

(canceled)

### Claim 10 (depends on 1)

The method of claim 1, wherein the virus is a Flaviviridae virus.

### Claim 11

(canceled)

### Claim 12

(canceled)

### Claim 13

(canceled)

### Claim 14 (depends on 1)

The method of claim 1, wherein R2A is hydrogen, halo, —CHF2 or —CN.

### Claim 15

(canceled)

### Claim 16

(canceled)

### Claim 17 (depends on 1)

The method of claim 1, wherein R2A is an unsubstituted C1-4 alkyl, an unsubstituted C2-4 alkenyl or an unsubstituted C2-4 alkynyl.

### Claim 18

(canceled)

### Claim 19

(canceled)

### Claim 20

(canceled)

### Claim 21 (depends on 1)

The method of claim 1, wherein R2A is —(CH2)1-6 halogen, —(CH2)1-6N3 or —(CH2)1-6NH2.

### Claim 22

(canceled)

### Claim 23

(canceled)

### Claim 24

(canceled)

### Claim 25

(canceled)

### Claim 26

(canceled)

### Claim 27 (depends on 1)

The method of claim 1, wherein R4A is H or halo.

### Claim 28

(canceled)

### Claim 29

(canceled)

### Claim 30

(canceled)

### Claim 31

(canceled)

### Claim 32 (depends on 1)

The method of claim 1, wherein R4A is OH, —OC(═O)R″B or an optionally substituted O-linked amino acid.

### Claim 33 (depends on 1)

The method of claim 1, wherein R4A is N3 or NR″B1R″B2.

### Claim 34 (depends on 1)

The method of claim 1, wherein R5A is H, halo or OH.

### Claim 35

(canceled)

### Claim 36

(canceled)

### Claim 37 (depends on 1)

The method of claim 1, wherein R5A is an optionally substituted C1-6 alkyl, an optionally substituted C2-6 alkenyl or an optionally substituted C2-6 alkynyl.

### Claim 38

(canceled)

### Claim 39

(canceled)

### Claim 40 (depends on 1)

The method of claim 1, wherein - - - - - - - - are both absent.

### Claim 41 (depends on 1)

The method of claim 1, wherein R1A is hydrogen.

### Claim 42 (depends on 1)

The method of claim 1, wherein R1A is an optionally substituted acyl or an optionally substituted O-linked amino acid.

### Claim 43 (depends on 1)

The method of claim 1, wherein R1A is

### Claim 44 (depends on 43)

The method of claim 43, wherein R1A is
and R6A and R7A are independently absent or hydrogen or R6A is
R7A, R12A and R13A are independently absent or hydrogen, R14A is O− or OH; and m is 0 or 1.

### Claim 45

(canceled)

### Claim 46

(canceled)

### Claim 47 (depends on 43)

The method of claim 43, wherein R1A is
and R6A and R7A are independently an optionally substituted C1-24 alkyl, an optionally substituted C2-24 alkenyl, an optionally substituted C2-24 alkynyl, an optionally substituted C3-6 cycloalkyl, an optionally substituted C3-6 cycloalkenyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted aryl(C1-6 alkyl), an optionally substituted *-(CR15AR16A)p—O—C1-24 alkyl or an optionally substituted *-(CR17AR18A)q—O—C1-24 alkenyl.

### Claim 48

(canceled)

### Claim 49 (depends on 43)

The method of claim 43, wherein R1A is
and R6A and R7A are independently

### Claim 50 (depends on 43)

The method of claim 43, wherein R1A is
and R6A and R7A are independently
or R6A and R7A are taken to together to form a moiety selected from the group consisting of an optionally substituted
and an optionally substituted
wherein the oxygens connected to R6A and R7A, the phosphorus and the moiety form a six-membered to ten-membered ring system.

### Claim 51

(canceled)

### Claim 52

(canceled)

### Claim 53

(canceled)

### Claim 54

(canceled)

### Claim 55 (depends on 43)

The method of claim 43, wherein R1A is
and R8A is an optionally substituted aryl or an optionally substituted heteroaryl, and R9A is an optionally substituted N-linked amino acid or an optionally substituted N-linked amino acid ester derivative.

### Claim 56

(canceled)

### Claim 57

(canceled)

### Claim 58

(canceled)

### Claim 59

(canceled)

### Claim 60

(canceled)

### Claim 61

(canceled)

### Claim 62

(canceled)

### Claim 63 (depends on 43)

The method of claim 43, wherein R1A is
and R10A and R11A are independently an optionally substituted N-linked amino acid or an optionally substituted N-linked amino acid ester derivative.

### Claim 64

(canceled)

### Claim 65

(canceled)

### Claim 66

(canceled)

### Claim 67

(canceled)

### Claim 68 (depends on 1)

The method of claim 1, wherein - - - - - - - - are each absent, and R3A is H or halo.

### Claim 69

(canceled)

### Claim 70

(canceled)

### Claim 71

(canceled)

### Claim 72 (depends on 1)

The method of claim 1, wherein - - - - - - - - are each absent, and R3A is OH, —OC(═O)R″A or an optionally substituted O-linked amino acid; or R3A and R4A are both an oxygen atom connected via a carbonyl to form a 5-membered ring.

### Claim 73

(canceled)

### Claim 74

(canceled)

### Claim 75

(canceled)

### Claim 76

(canceled)

### Claim 77

(canceled)

### Claim 78

(canceled)

### Claim 79 (depends on 1)

The method of claim 1, wherein RA is hydrogen or deuterium.

### Claim 80

(canceled)

### Claim 81 (depends on 1)

The method of claim 1, wherein RA is an unsubstituted C1-3 alkyl, an unsubstituted C2-4 alkenyl, an unsubstituted C2-3 alkynyl or cyano.

### Claim 82

(canceled)

### Claim 83

(canceled)

### Claim 84

(canceled)

### Claim 85 (depends on 1)

The method of claim 1, wherein Ra1 and Ra2 are both hydrogen.

### Claim 86 (depends on 1)

The method of claim 1, wherein Ra1 and Ra2 are both deuterium.

### Claim 87 (depends on 1)

The use method of claim 1, wherein R1A is selected from the group consisting of:
wherein:
RA2 is selected from the group consisting of hydrogen, halogen and NHRJ2, wherein RJ2 is selected from the group consisting of hydrogen, —C(═O)RK2 and —C(═O)ORL2;
RB2 is halogen or NHRW2, wherein RW2 is selected from the group consisting of hydrogen, an optionally substituted C1-6 alkyl, an optionally substituted C2-6 alkenyl, an optionally substituted C3-8 cycloalkyl, —C(═O)RM2 and —C(═O)ORN2;
RC2 is hydrogen or NHRO2, wherein RO2 is selected from the group consisting of hydrogen, —C(═O)RP2 and —C(═O)ORQ2;
RD2 is selected from the group consisting of hydrogen, deuterium, halogen, an optionally substituted C1-6 alkyl, an optionally substituted C2-6 alkenyl and an optionally substituted C2-6 alkynyl;
RE2 is selected from the group consisting of hydrogen, hydroxy, an optionally substituted C1-6 alkyl, an optionally substituted C3-8 cycloalkyl, —C(═O)RR2 and —C(═O)ORS2;
RF2 is selected from the group consisting of hydrogen, halogen, an optionally substituted C1-6 alkyl, an optionally substituted C2-6 alkenyl and an optionally substituted C2-6 alkynyl;
Y2 and Y3 are independently N or CRI2, wherein RI2 is selected from the group consisting of hydrogen, halogen, an optionally substituted C1-6 alkyl, an optionally substituted C2-6 alkenyl and an optionally substituted C2-6 alkynyl;
W1 is NH, —NCH2—OC(═O)CH(NH2)—CH(CH3)2 or —(CH2)1-2—O—P(═O)(OW1A)2, wherein W1A is selected from the group consisting of absent, hydrogen and an optionally substituted C1-6 alkyl;
RG2 is an optionally substituted C1-6 alkyl;
RH2 is hydrogen or NHRT2, wherein RT2 is independently selected from the group consisting of hydrogen, —C(═O)RU2 and —C(═O)ORV2; and
RK2, RL2, RM2, RN2, RP2, RQ2 RR2, RS2, RU2 and RV2 are independently selected from the group consisting of hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, C3-6 cycloalkenyl, C6-10 aryl, heteroaryl, heterocyclyl, aryl(C1-6 alkyl), heteroaryl(C1-6 alkyl) and heterocyclyl(C1-6 alkyl).

### Claim 88 (depends on 87)

The method of claim 87, wherein B1A is

### Claim 89

(canceled)

### Claim 90

(canceled)

### Claim 91

(canceled)

### Claim 92

(canceled)

### Claim 93

(canceled)

### Claim 94 (depends on 1)

The method of claim 1, wherein the compound is selected from the group consisting of:
or a pharmaceutically acceptable salt of the foregoing.

### Claim 95 (depends on 1)

The method of claim 1, wherein the compound is selected from the group consisting of:
or a pharmaceutically acceptable salt of the foregoing.

### Claim 96 (depends on 1)

The method of claim 1, wherein the compound is selected from the group consisting of:
or a pharmaceutically acceptable salt of the foregoing.

### Claim 97

A compound of Formula (II), or a pharmaceutically acceptable salt thereof, wherein the compound of Formula (II) has the structure:
wherein:
B1C is an optionally substituted heterocyclic base or an optionally substituted heterocyclic base with a protected amino group;
- - - - - - - - is absent or a single bond, provided that both - - - - - - - - are absent or both - - - - - - - - are a single bond;
when - - - - - - - - are both absent, then Z2 is absent, O2 is OR1C, R3C is selected from the group consisting of H, halo, OH, —OC(═O)R″C and an optionally substituted O-linked amino acid, R4C is selected from the group consisting of H, OH, halo, N3, —OC(═O)R″D, an optionally substituted O-linked amino acid and NR″D1R″D2, or R3C and R4C are both an oxygen atom connected via a carbonyl to form a 5-membered ring;
when - - - - - - - - are each a single bond, then Z2 is
O2 is O, R3C is O; R4C is selected from the group consisting of OH, halo, N3, —OC(═O)R″D, an optionally substituted O-linked amino acid and NR″D1R″D2; and R1D is selected from the group consisting of O−, OH, an —O-optionally substituted C1-6 alkyl,
an optionally substituted N-linked amino acid and an optionally substituted N-linked amino acid ester derivative;
Rc1 and Rc2 are independently hydrogen or deuterium;
RC is hydrogen, deuterium, an unsubstituted C1-3 alkyl, an unsubstituted C2-4 alkenyl, an unsubstituted C2-3 alkynyl or cyano;
R1C is selected from the group consisting of hydrogen, an optionally substituted acyl, an optionally substituted O-linked amino acid,
R2C is hydrogen, halo, an unsubstituted C1-4 alkyl, an unsubstituted C2-4 alkenyl, an unsubstituted C2-4 alkynyl, —CHF2, —(CH2)1-6 halogen, —(CH2)1-6N3, —(CH2)1-6NH2 or —CN;
R5C is selected from the group consisting of H, halo, OH, an optionally substituted C1-6 alkyl, an optionally substituted C2-6 alkenyl and an optionally substituted C2-6 alkynyl;
R6C, R7C and R8C are independently selected from the group consisting of absent, hydrogen, an optionally substituted C1-24 alkyl, an optionally substituted C2-24 alkenyl, an optionally substituted C2-24 alkynyl, an optionally substituted C3-6 cycloalkyl, an optionally substituted C3-6 cycloalkenyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted aryl(C1-6 alkyl), an optionally substituted *-(CR15CR16C)f—O—C1-24 alkyl, an optionally substituted *-(CR17CR18C)g—O—C1-24 alkenyl,
or
R6C is
and R7C is absent or hydrogen; or
R6C and R7C are taken together to form a moiety selected from the group consisting of an optionally substituted
and an optionally substituted
wherein the oxygens connected to R6C and R7C, the phosphorus and the moiety form a six-membered to ten-membered ring system;
R9C is independently selected from the group consisting of an optionally substituted C1-24 alkyl, an optionally substituted C2-24 alkenyl, an optionally substituted C2-24 alkynyl, an optionally substituted C3-6 cycloalkyl, an optionally substituted C3-6 cycloalkenyl, NR30CR31C, an optionally substituted N-linked amino acid and an optionally substituted N-linked amino acid ester derivative;
R10C and R11C are independently an optionally substituted N-linked amino acid or an optionally substituted N-linked amino acid ester derivative;
R12C and R13C are independently absent or hydrogen;
R14C is O—, OH or methyl;
each R15D, each R16C, each R17C and each R18C are independently hydrogen, an optionally substituted C1-24 alkyl or an alkoxy;
R19C, R20C, R22C, R23C, R2D, R3D, R5D and R6D are independently selected from the group consisting of hydrogen, an optionally substituted C1-24 alkyl and an optionally substituted aryl;
R21C and R4D are independently selected from the group consisting of hydrogen, an optionally substituted C1-24 alkyl, an optionally substituted aryl, an optionally substituted —O—C1-24 alkyl, an optionally substituted —O-aryl, an optionally substituted —O-heteroaryl and an optionally substituted —O-monocyclic heterocyclyl;
R24C and R7D are independently selected from the group consisting of hydrogen, an optionally substituted C1-24 alkyl, an optionally substituted aryl, an optionally substituted —O—C1-24 alkyl, an optionally substituted —O-aryl, an optionally substituted —O-heteroaryl, an optionally substituted —O-monocyclic heterocyclyl and
R25C, R26C, R29C, R8D and R9D are independently selected from the group consisting of hydrogen, an optionally substituted C1-24 alkyl and an optionally substituted aryl;
R27C1 and R27C2 are independently selected from the group consisting of —C≡N, an optionally substituted C2-8 organylcarbonyl, an optionally substituted C2-8 alkoxycarbonyl and an optionally substituted C2-8 organylaminocarbonyl;
R28C is selected from the group consisting of hydrogen, an optionally substituted C1-24 alkyl, an optionally substituted C2-24 alkenyl, an optionally substituted C2-24 alkynyl, an optionally substituted C3-6 cycloalkyl and an optionally substituted C3-6 cycloalkenyl;
R30C and R31C are independently selected from the group consisting of hydrogen, an optionally substituted C1-24 alkyl, an optionally substituted C2-24 alkenyl, an optionally substituted C2-24 alkynyl, an optionally substituted C3-6 cycloalkyl, an optionally substituted C3-6 cycloalkenyl and an optionally substituted aryl(C1-4 alkyl);
R″C and each R″D are independently an optionally substituted C1-24 alkyl;
each R″D1 and each R″D2 are independently hydrogen or an optionally substituted C1-24 alkyl;
is 0 or 1,
f and g are independently 1, 2 or 3;
h and j are independently 0, 1, 2 or 3;
b is 1 or 2;
k and l is independently 3, 4 or 5;
c and d are 1; and
Z1C, Z2C, Z3C, Z4C, Z1D and Z2D are independently O or S;
provided that when R2C is halo; - - - - - - - - are both absent; Z2 is absent; O2 is OR1C;
B1C is selected from the group consisting of an optionally substituted
an optionally substituted
an optionally substituted
an optionally substituted
an optionally substituted
and an optionally substituted
wherein Ra2 is an optionally substituted C1-6 alkyl or an optionally substituted C3-6 cycloalkyl, Ra3 and Ra4 are independently selected from the group consisting of hydrogen, an unsubstituted C1-6 alkyl, an unsubstituted C3-6 alkenyl, an unsubstituted C3-6 alkynyl and an unsubstituted C3-6 cycloalkyl, Ra5 is NHRa8, and Ra6 is hydrogen, halogen or NHRa9; Ra7 is NHRa10; Ra8 is selected from the group consisting of hydrogen, an optionally substituted C1-6 alkyl, an optionally substituted C3-6 alkenyl, an optionally substituted C3-6 cycloalkyl, —C(═O)Ra11 and —C(═O)ORa12; Ra9 is selected from the group consisting of hydrogen, an optionally substituted C1-6 alkyl, an optionally substituted C3-6 alkenyl, an optionally substituted C3-6 cycloalkyl, —C(═O)Ra13 and —C(═O)ORa14; Ra10 is selected from the group consisting of hydrogen, an optionally substituted C1-6 alkyl, an optionally substituted C3-6 alkenyl, an optionally substituted C3-6 cycloalkyl, —C(═O)Ra15 and —C(═O)ORa16; Xa1 is N or —CRal7; Ra17 is selected from the group consisting of hydrogen, halogen, an optionally substituted C1-6 alkyl, an optionally substituted C2-6 alkenyl and an optionally substituted C2-6 alkynyl; Ra11, Ra12, Ra13, Ra14, R15 and Ra16 are independently selected from the group consisting of C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, C3-6 cycloalkenyl, C6-10 aryl, heteroaryl, heterocyclyl, aryl(C1-6 alkyl), heteroaryl(C1-6 alkyl) and heterocyclyl(C1-6 alkyl); then R3C is selected from the group consisting of H, halo and an optionally substituted O-linked amino acid; and R4C is selected from the group consisting of OH, halo, N3, —OC(═O)R″D, an optionally substituted O-linked amino acid and NR″D1R″D2; or then R3C is selected from the group consisting of H, halo, OH, —OC(═O)R″C and an optionally substituted O-linked amino acid and R4C is an optionally substituted O-linked amino acid; or then R1C is
wherein R6C and R7C are independently
wherein h is 1, 2 or 3,
or then R1C is
wherein R6C and R7C are taken together to form a moiety selected from the group consisting of an optionally substituted
and an optionally substituted
wherein the oxygens connected to R6C and R7C, the phosphorus and the moiety form a six-membered to ten-membered ring system;
provided that when R2C is halo; - - - - - - - - are each a single bond; then R4C is —OC(═O)R″D or an optionally substituted O-linked amino acid;
provided that when R2C is an unsubstituted C1-4 alkyl, an unsubstituted C2-4 alkenyl, an unsubstituted C2-4 alkynyl, —(CH2)1-6 halogen, —(CH2)1-6N3 or —(CH2)1-6NH2; - - - - - - - - are both absent; Z2 is absent; O2 is OR1C; R3C is OH, —OC(═O)R″C or an optionally substituted O-linked amino acid; and R4C is halo; then R5C is selected from the group consisting of an optionally substituted C1-6 alkyl, an optionally substituted C2-6 alkenyl and an optionally substituted C2-6 alkynyl;
provided that when R2C is an unsubstituted C1-4 alkyl, an unsubstituted C2-4 alkenyl, an unsubstituted C2-4 alkynyl, —(CH2)1-6 halogen, —(CH2)1-6N3 or —(CH2)1-6NH2; - - - - - - - - are both absent; Z2 is absent; O2 is OR1C; R4C is halo; and R5C is H or halo; then R3C is H or halo;
provided that when R2C is an unsubstituted C1-4 alkyl, an unsubstituted C2-4 alkenyl, an unsubstituted C2-4 alkynyl or —(CH2)1-6 halogen; - - - - - - - - are both absent; Z2 is absent; O2 is OR1C; R3C is OH, —OC(═O)R″C or an optionally substituted O-linked amino acid; R4C is halo; R5C is H or halo; and R1C is
then at least one of R6C and R7C is
wherein R21C is independently selected from the group consisting of an optionally substituted —O-heteroaryl and an optionally substituted —O-monocyclic heterocyclyl; or then at least one of R6C and R7C is
wherein s is 1, 2 or 3; or then at least one of R6C and R7C is
wherein s is 0 and R24C is an optionally substituted —O-heteroaryl or an optionally substituted —O-monocyclic heterocyclyl;
provided that when R2C is an unsubstituted C1-4 alkyl, an unsubstituted C2-4 alkenyl, an unsubstituted C2-4 alkynyl or —(CH2)1-6 halogen; - - - - - - - - are both absent; Z2 is absent; O2 is OR1C; R3C is OH, —OC(═O)R″C or an optionally substituted O-linked amino acid; R4C is halo; R5C is H or halo; and R1C is
then R8C is
wherein R21C is independently selected from the group consisting of an optionally substituted —O-heteroaryl and an optionally substituted —O-monocyclic heterocyclyl; or then R8C is
wherein s is 1, 2 or 3; or then R8C is
wherein s is 0 and R24C is an optionally substituted —O-heteroaryl, an optionally substituted —O-monocyclic heterocyclyl or
provided that when - - - - - - - - are both absent; Z2 is absent; O2 is OH; R2C is methyl; R3C is OH; then R4C is halo, —OC(═O)R″D or an optionally substituted O-linked amino acid; and
provided that when - - - - - - - - are both absent; Z2 is absent; O2 is OR1C; R2C is fluoro; R3C is OH or —OC(═O)R″C; R4C is fluoro; and R5C is methyl, ethyl or ethenyl; then R1C cannot be selected from the group consisting of H,
wherein R8C is an unsubstituted aryl; R9C is
and Z2 is oxygen.

### Claim 98 (depends on 97)

The compound of claim 97, wherein R2C is hydrogen, halo, —CHF2 or —CN.

### Claim 99

(canceled)

### Claim 100

(canceled)

### Claim 101 (depends on 97)

The compound of claim 97, wherein R2C is an unsubstituted C1-4 alkyl, an unsubstituted C2-4 or an unsubstituted C2-4 alkynyl.

### Claim 102

(canceled)

### Claim 103

(canceled)

### Claim 104

(canceled)

### Claim 105 (depends on 97)

The compound of claim 97, wherein R2C is —(CH2)1-6 halogen, —(CH2)1-6N3 or —(CH2)1-6NH2.

### Claim 106

(canceled)

### Claim 107

(canceled)

### Claim 108

(canceled)

### Claim 109

(canceled)

### Claim 110

(canceled)

### Claim 111 (depends on 97)

The compound of claim 97, wherein R4C is H.

### Claim 112 (depends on 97)

The compound of claim 97, wherein - - - - - - - - are both absent.

### Claim 113

The compound of 112, wherein R3C is H or halo.

### Claim 114

(canceled)

### Claim 115

(canceled)

### Claim 116

(canceled)

### Claim 117 (depends on 97)

The compound of claim 97, wherein R4C is H or halo.

### Claim 118

(canceled)

### Claim 119

(canceled)

### Claim 120

(canceled)

### Claim 121 (depends on 97)

The compound of claim 97, wherein R4C is OH, —OC(═O)R″D or an optionally substituted O-linked amino acid.

### Claim 122 (depends on 97)

The compound of claim 97, wherein R4C is N3, or NR″D1R″D2.

### Claim 123

(canceled)

### Claim 124

(canceled)

### Claim 125

(canceled)

### Claim 126 (depends on 97)

The compound of claim 97, wherein R5C is H, halo or OH.

### Claim 127

(canceled)

### Claim 128

(canceled)

### Claim 129 (depends on 97)

The compound of claim 97, wherein R5C is an optionally substituted C1-6 alkyl, an optionally substituted C2-6 alkenyl or an optionally substituted C2-6 alkynyl.

### Claim 130

(canceled)

### Claim 131

(canceled)

### Claim 132 (depends on 97)

The compound of claim 97, wherein RC is hydrogen or deuterium.

### Claim 133

(canceled)

### Claim 134 (depends on 97)

The compound of claim 97, wherein RC is an unsubstituted C1-3 alkyl, an unsubstituted C2-4 alkenyl or an unsubstituted C2-3 alkynyl.

### Claim 135

(canceled)

### Claim 136

(canceled)

### Claim 137

(canceled)

### Claim 138 (depends on 97)

The compound of claim 97, wherein Rc1 and Rc2 are both hydrogen.

### Claim 139 (depends on 97)

The compound of claim 97, wherein Rc1 and Rc2 are both deuterium.

### Claim 140 (depends on 97)

The compound of claim 97, wherein B1C is selected from the group consisting of:
wherein:
RAA2 is selected from the group consisting of hydrogen, halogen and NHRJJ2, wherein RJJ2 is selected from the group consisting of hydrogen, —C(═O)RKK2 and —C(═O)ORLL2;
RBB2 is halogen or NHRWW2, wherein RWW2 is selected from the group consisting of hydrogen, an optionally substituted C1-6 alkyl, an optionally substituted C2-6 alkenyl, an optionally substituted C3-8 cycloalkyl, —C(═O)RMM2 and —C(═O)ORNN2;
RCC2 is hydrogen or NHROO2, wherein RO2 is selected from the group consisting of hydrogen, —C(═O)RPP2 and —C(═O)ORQQ2;
RDD2 is selected from the group consisting of hydrogen, deuterium, halogen, an optionally substituted C1-6 alkyl, an optionally substituted C2-6 alkenyl and an optionally substituted C2-6 alkynyl;
REE2 is selected from the group consisting of hydrogen, hydroxy, an optionally substituted C1-6 alkyl, an optionally substituted C3-8 cycloalkyl, —C(═O)R′2 and —C(═O)ORSS2;
RFF2 is selected from the group consisting of hydrogen, halogen, an optionally substituted C1-6alkyl, an optionally substituted C2-6 alkenyl and an optionally substituted C2-6 alkynyl;
Y4 and Y5 are independently N or CRII2, wherein RII2 is selected from the group consisting of hydrogen, halogen, an optionally substituted C1-6 alkyl, an optionally substituted C2-6-alkenyl and an optionally substituted C2-6-alkynyl;
W2 is NH, —NCH2—OC(═O)CH(NH2)—CH(CH3)2 or —(CH2)1-2—O—P(═O)(OW2C)2, wherein W2C is selected from the group consisting of absent, hydrogen and an optionally substituted C1-6 alkyl;
RGG2 is an optionally substituted C1-6 alkyl;
RHH2 is hydrogen or NHRTT2, wherein RTT2 is independently selected from the group consisting of hydrogen, —C(═O)RUU2 and —C(═O)ORVV2; and
RKK2, RLL2, RMM2, RNN2, RPP2, RQQ2RRR2, RSS2, RUU2 and RVV2 are independently selected from the group consisting of hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, C3-6 cycloalkenyl, C6-10 aryl, heteroaryl, heterocyclyl, aryl(C1-6 alkyl), heteroaryl(C1-6 alkyl) and heterocyclyl(C1-6 alkyl).

### Claim 141 (depends on 140)

The compound of claim 140, wherein B1C is

### Claim 142

(canceled)

### Claim 143

(canceled)

### Claim 144

(canceled)

### Claim 145

(canceled)

### Claim 146

(canceled)

### Claim 147

A compound selected from the group consisting of:
or a pharmaceutically acceptable salt of the foregoing.

### Claim 148

A compound selected from the group consisting of:
or a pharmaceutically acceptable salt of the foregoing.

### Claim 149

A compound selected from the group consisting of:
or a pharmaceutically acceptable salt of the foregoing.

### Claim 150 (depends on 97)

A pharmaceutical composition comprising an effective amount of a compound of claim 97, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent, excipient or combination thereof.

### Claim 151

(canceled)

### Claim 152

(canceled)

### Claim 153

(canceled)

### Claim 154 (depends on 1)

The method of claim 1, wherein the compound of Formula (I) is
or a pharmaceutically acceptable salt thereof.

### Claim 155 (depends on 1)

The method of claim 1, wherein the compound of Formula (I) is
or a pharmaceutically acceptable salt thereof.

### Claim 156 (depends on 1)

The method of claim 1, wherein the compound of Formula (I) is
or a pharmaceutically acceptable salt thereof.

### Claim 157 (depends on 1)

The method of claim 1, wherein the compound of Formula (I) is
or a pharmaceutically acceptable salt thereof.

### Claim 158 (depends on 1)

The method of claim 1, wherein the compound of Formula (I) is
or a pharmaceutically acceptable salt thereof.

### Claim 159 (depends on 1)

The method of claim 1, wherein the compound of Formula (I) is
or a pharmaceutically acceptable salt thereof.

### Claim 160 (depends on 1)

The method of claim 1, wherein the compound of Formula (I) is
or a pharmaceutically acceptable salt thereof.

### Claim 161 (depends on 1)

The method of claim 1, wherein the compound of Formula (I) is
or a pharmaceutically acceptable salt thereof.

### Claim 162 (depends on 1)

The method of claim 1, wherein the compound of Formula (I) is

### Claim 163 (depends on 97)

The compound of claim 97, wherein the compound of Formula (I) is
or a pharmaceutically acceptable salt thereof.

### Claim 164 (depends on 97)

The compound of claim 97, wherein the compound of Formula (I) is
or a pharmaceutically acceptable salt thereof.

### Claim 165 (depends on 97)

The compound of claim 97, wherein the compound of Formula (I) is
or a pharmaceutically acceptable salt thereof.

### Claim 166 (depends on 97)

The compound of claim 97, wherein the compound of Formula (I) is
or a pharmaceutically acceptable salt thereof.

### Claim 167 (depends on 97)

The compound of claim 97, wherein the compound of Formula (I) is
or a pharmaceutically acceptable salt thereof.

### Claim 168 (depends on 97)

The compound of claim 97, wherein the compound of Formula (I) is
or a pharmaceutically acceptable salt thereof.

### Claim 169 (depends on 97)

The compound of claim 97, wherein the compound of Formula (I) is
or a pharmaceutically acceptable salt thereof.

### Claim 170 (depends on 97)

The compound of claim 97, wherein the compound of Formula (I) is
or a pharmaceutically acceptable salt thereof.

### Claim 171 (depends on 97)

The compound of claim 97, wherein the compound of Formula (I) is
